The NMDA receptor is believed to be important in a wide range of nervous system functions including neuronal migration, synapse formation, learning and memory. In addition, it is involved in excitotoxic neuronal cell death that occurs in a variety of acute and chronic neurological disorders. Besides agonist/coagonist sites, other modulator sites, including the butyrophenone site, may regulate the NMDA receptor. It has been shown that many neuronal modulator mechanisms may be co-coordinated by a group of binding proteins that both clusters NMDA receptors and links them to signalling pathways within the cell. We have found that 5'-guanylylimidodiphosphate (Gpp(NH)p) inhibited the binding of . Affinity-purified preparations of the NMDA receptor, which were immunoprecipitated by anti-p21
INTRODUCTION
The NMDA receptor is believed to be important in a wide range of nervous system functions including neuronal migration, synapse formation and learning and memory. In addition, it is involved in the excitotoxic neuronal cell death that occurs in a variety of acute and chronic neurological disorders (see [21] for a review).
It has been shown that many neuronal modulator mechanisms may be co-coordinated by a group of binding proteins that both clusters NMDA receptors and links them to signalling pathways within the cell. The NR2A and NR2B subunits of the receptor bind to the SH2 domains of phospholipase C in a tyrosine phosphorylationdependent manner [11] . Members of the PSD-95/SAP90 family will also cluster NMDA receptors when coexpressed in transfected cells and are associated with the NMDA receptor in neuronal membranes [14, 18] . PSD-95 also binds to non-inducible nitric oxide synthase (nNOS) by interaction of its PDZ domain with a PDZ domain in nNOS [2] thus suggesting that PDZ domains may participate in the assembly of macromolecular signalling complexes involving NMDA receptors and one or more signalling molecules at the postsynaptic density.
One of the possible signalling proteins participating in the formation of the macromolecular signalling complexes in postsynaptic density may be p21
Ras [20] . It has been found that a p21
Ras -activating protein, SynGAP (GTPase activating protein), is exclusively localized at synapses and associated with the PSD95 and NMDA receptors [7, 13] . It has also been shown that NMDA receptor stimulation leads to activation of p21
Ras through generation of nitric oxide (NO) in a cGMP-dependent pathway via nNOS [24] . These data suggest that p21
Ras may also participate in the formation of supramolecular complexes with NMDA receptors.
Besides its agonist/coagonist sites, the NMDA receptor is regulated by other modulator action, including voltagedependent blocking of the channel by Mg 2+ , voltageindependent actions of Zn 2+ , the redox state of the receptor, and sites for arachidonic acid, ethanol, neurosteroids, pH and polyamines [23] . It has been found that haloperidol, a therapeutically useful antipsychotic drug, inhibits neuronal NMDA responses and has neuroprotective effects against NMDA-induced neurotoxicity [12, 19] . Results from Whittemore et al. [22] suggest that a noncompetitive allosteric modulator site expressed by isoforms of the receptor containing the NR1/NR2B subunit mediates haloperidol's action on the NMDA receptor. The ligand binding experiments of [8] , as well as point mutation studies [3] showed that haloperidol interacts with polyamine sensitive sites of the NR2B subunits.
Haloperidol induces the expression of immediate early genes [15] and genes associated with synaptic plasticity [9] . NMDA receptor antagonists diminished the c-fos mRNA increase produced by haloperidol, indicating that the NMDA receptor is involved in this process [17, 25] . However, the signalling pathway whereby haloperidol induces the expression of genes through the NMDA receptor is unknown. In this study we have tried to demonstrate that the action of haloperidol may be mediated by p21
Ras , which forms a macromolecular complex with the NMDA receptor.
MATERIALS AND METHODS
Membrane preparations from rat cortex or hippocampus were obtained after tissue homogenization in 20 volumes of ice-cold 0.32 M sucrose, containing 0.1 M phenylmethylsulphonyl fluoride (PMSF), 3 mM EDTA, 5 units/ml aprotinin and 5 µg/ml pepstatin A. The homogenate was centrifuged at 1000 g for 10 min, the pellet was removed, and the supernatant was centrifuged at 20000 g for 20 min. The pellet was resuspended in 20 mM TrisHCl, pH 7.4 buffer, containing 0.1 mM PMSF, 2 mM EDTA, 5 µg/ml pepstatin and 5 units/ml aprotinin (buffer A) to yield a suspension of 5 mg protein/ml and frozen at −40 °C until use.
Solubilization was carried out using 1% sodium deoxycholate at a detergent/protein ratio = 4/1 (mg/mg) in buffer A during 1 hour at 4 °C followed by centrifugation at 100000 g for 1 hour. The final supernatant was dialyzed against 20 mM Tris-HCl (pH 7.4) containing 2 mM EDTA and 0.1 mM PMSF (buffer B) and was applied on either dextrorphan-Sepharose or trihexyphenidyl (THP)-Sepharose columns (1 x 10 cm) pre-equilibrated in buffer A. The columns were washed with 40 ml buffer A and matrix-binding proteins were eluted by 100 mM dextrorphan or by 100 mM phencyclidine in buffer A. The eluates were dialyzed against buffer B and their binding activity was determined.
[ The binding of THP and dextrorphan to Sepharose 4B was carried out as Egly et al. [10] suggested for triflufenazine immobilization [6] . Protein concentration was determined using a dye-binding method (Bio-Rad).
3.RESULTS

Binding experiments
The guanine nucleotide analogue, 5'-guanylylimidodiphosphate (Gpp(NH)p), was examined for its effect on 3 H-haloperidol binding to rat cortical and hippocampal synaptic membranes. It was found that Gpp(NH)p inhibits the binding of 3 H-haloperidol to the both cortical (IC 50 = 1012.8 nM, data not shown) and hippocampal (IC 50 = 900.6 nM) synaptic membranes with high affinity ( fig.1 ). On the contrary haloperidol reduces the binding (Table 1 ). These data demonstrate that the action of haloperidol on the binding of guanine nucleotide with synaptic membranes is specific and can be directed at a system of p21 Ras .
Purification and characterization of haloperidol binding proteins
It has been shown previously that many neuronal modulator mechanisms may be co-coordinated by a group of binding proteins that both clusters NMDA receptors and links them to signalling pathways within the cell [21] . The possible signalling proteins participating in the formation of the macromolecular signalling complexes in postsynaptic density may be nNOS and p21
Ras [20] . For identification of the target protein for haloperidol in the supramolecular complex of NMDA receptors the solubilization and affinity chromatography was performed. For this purpose, the final supernatant followed solubilization by 1% sodium deoxycholate (see Materials and Methods) and subsequent centrifugation was applied either on THP-Sepharose or dextrorphan-sepharose columns. Proteins binding THP-Sepharose or dextrorphanSepharose from columns were eluted by 10 µM phencyclidine or by 10 µM dextrorphan respectively. SDS-PAG electrophoresis has shown that eluates from THP-sepharose (preparation 1) contain 5 major protein fractions with molecular weights of 23000, 48000, 56000, 11500 and 125000, and eluates from dextrorphansepharose (preparation 2) contain 6 protein fractions with molecular weights of 23000, 32000, 48000, 56000, 11500, 125000 (data not shown). As the dextrorphan has higher affinity to a sigma receptor, is possible that the additional protein in the preparation 2 is one of the sigma binding proteins.
Pharmacological specificities of solubilized and both affinity-purified preparations were studied by competition binding experiments. MK-801 was found to have the highest affinity for the proteins of solubilized preparations, while pentazocine, a sigma opiate agonist, the lowest (data not shown). This shows that sodium deoxycholate solubilizes NMDA-glutamate receptors highly effectively, but sigma-binding proteins relatively ineffectively. The pharmacological profile of the affinity-purified preparations does not significantly differ by specificity from the solubilized preparations, indicating that the pharmacological specificity of NMDA receptors does not change during affinity chromatography.
It was also revealed that both preparation 1 and preparation 2 bound [ 3 H] GppNp and did not lose sensitivity to haloperidol. The data for haloperidol are presented in Table 1 ; similar results are obtained for the other drugs. In spite of the fact that the IC 50 is in this case lower against the membranous preparation, the specificity of interaction with the drugs is the same (data not shown). Thus it is possible to conclude that the supramolecular complex of NMDA-receptor after affinity chromatography contains proteins binding in the same way as haloperidol and GppNHp.
Immunoprecipitation of the NMDA receptor
For identification of proteins in the supramolecular complex of NMDA receptor both affinity-purified preparations were immunoprecipitated by anti-Ras and analyzed by Western-blot. It was found that only the ε2 (NR2A/NR2B) subunits of the NMDA receptors were present in both immunoprecipitated preparations. In addition it was revealed that both preparations contained nNOS and did not contain the ε1 subunit of the NMDA receptor and SAP ( fig. 3 ).
Thus, it is possible to conclude that the supramolecular complex obtained after dextrorphan-Sepharose and THPSepharose chromatography contains the NR2A/NR2B subunits of the NMDA receptor, p21Ras and nNOS. Furthermore this macromolecular complex is sensitive to haloperidol and binds guanine nucleotides. Figure 3 . Co-immunoprecipitation of NR2A/NR2B subunits of NMDA-receptor and nNOS by anti-Ras. Preparations 1 and 2 were precipitated using the Ras antibody, separated on SDS-PAGE, and analyzed using immunoblots probed with nNOS, NR2A/NR2B subunits and SAP antibodies as desribed in "Materials and Methods". Lanes 1 and 2 -nNOS in preparations 1 and 2 respectively; lanes 3 and 4 -NR2A/NR2B in preparations 1 and 2 respectively; lane 5 -SAP(PSD-95). The blot is representative of three independent experiments.
DISCUSSION
Several PDZ-containing proteins have been shown to interact closely with ion-channel linked receptors (see for review [5] ). PSD-95 and PSD-93 were reported to interact directly with the C-terminal domains of two different subunits (NR2A and NR2B) of the NMDA receptor [1, 14] . The multivalent PDZ-containing protein CIPP (channel interacting PDZ-domain protein) was shown to bind to all four NR2 subunits [16] . On the other hand nNOS and synaptic Ras-GTPase activating protein (synGap),which have been reported [7, 13] to interact with PDZ-containing proteins, could further contribute to a complex protein scaffold. Our data has shown that the affinity-purified NMDA receptor preparation was immunoprecipitated by anti-Ras and contained nNOS. The protein complex does not contain SAP, however, and this fact indicates that the interaction of Ras and nNOS with the NR2B subunit is possibly carried out by other proteins, such as PSD-93 [1] , CIPP [16] or SAP102 [13] .
Ras signalling at the postsynaptic membrane may be involved in the modulation of excitatory synaptic transmission [20] . On the basis of our results it is possible to conclude that the macromolecular complex containing NR2B and Ras may be directly regulated by haloperidol. As shown in fig. 1 , haloperidol decreases the binding of 3 H-GppNp with synaptic membranes in a dose-dependent manner. Neither PCP, MK-801, dextrorphan nor pentazocine change the binding of 3 H-GppNp with synaptic membranes, which suggests that haloperidol binds elsewhere than at the PCP-site of the NMDA receptor. Ilyin et al. [12] indicated that haloperidol selectively inhibits NMDA receptors composed of NR1 and NR2B subunits by acting at a noncompetitive allosteric site distinct from the glutamate-, glycine-and PCP-binding sites, but related to the ifenprodil binding sites. Brimecombe et al. [3] found an NR2B point mutation affecting the haloperidol and CP101 (ifenprodil analogue) sensitivity of a single recombinant NMDA receptor. Together, these observations suggest that the unique effect of haloperidol on 3 H-GppHp binding (and possibly on the activity of p21 Ras ) may be mediated by the haloperidol/ifenprodil binding sites of the NMDA receptor. Accordingly, it is possible to conclude that regulation of the Ras-signalling pathway via the NMDA receptor may be carried out by polyamine (ifenprodil) sites.
